

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/565,238
Filing Date	January 19, 2006
First Named Inventor	Pinna FISHMAN
Group Art Unit	9164
Examiner Name	Not Yet Known
Attorney Docket Number	FISHMAN=19B

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AF	B. A. WALKER et al., "Adenosine A3 receptor expression and function in eosinophils", <u>American Journal of Respiratory Cell and Molecular Biology</u> , Vol. 16, No. 5, pages 531-537, May 1997.	
	AG	P. G. BARALDI et al., "A3 Adenosine Receptor Ligands: History and Perspectives", <u>Medicinal Research Reviews</u> , Vol. 20, No. 2, pages 103-128, March 2000.	
	AH	Y. KOHNO et al., "Activation of A3 Adenosine Receptors on Human Eosinophils Elevates Intracellular Calcium", <u>Blood</u> , Vol. 88, No. 9, pages 3569-3574, November 1, 1996.	
	AI	P. FISHMAN et al., "Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells", <u>Oncogene</u> , Vol. 21, pages 4060-4064, 2002.	
	AJ	P. FISHMAN et al., "Targeting the A3 adenosine receptor for cancer therapy: inhibition of Prostate carcinoma cell growth by A ₃ AR agonist", <u>Anticancer Res.</u> , Vol. 23, pages 2077-2083, 2003.	
	AK	L. MADI et al., "A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition", <u>J. Bio. Chem.</u> , Vol. 278, pages 42121-42130, 2003.	
	AL	G. OHANA et al., "Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist IB-CF101", <u>British J. Cancer</u> , Vol. 89, pages 1552-1558, 2003.	
	AM	P. FISHMAN et al., "An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 β and NF- κ B", <u>Oncogene</u> , Vol. 23, pages 2465-2471, 2004.	
	AN	C. SZABO et al., "Suppression of macrophage inflammatory protein (MIP)-1 α production and collagen-induced arthritis by adenosine receptor agonists", <u>British J. Pharmacology</u> , Vol. 125, pages 379-387, 1998.	
	AO	J. MABLEY et al., "The adenosine A ₃ receptor agonist, N ⁶ -(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis", <u>European J. Pharmacology</u> , Vol. 466, pages 323-329, 2003.	
	AP	E. BAHARAV et al., "The effect of adenosine and the A ₃ adenosine receptor agonist IB-MECA on joint inflammation and autoimmune diseases models", <u>Inter. J. Mol. Med.</u> , Vol. 10 (supplement 1), page S104, abstract 499, 2002.	
	AQ	M. MONTESINOS et al., "Adenosine A _{2A} or A ₃ receptors are required for inhibition of inflammation by methotrexate and its analog MX-68", <u>Arthritis & Rheumatism</u> , Vol. 48, pages 240-247, 2003.	
	AR	L. MADI et al., "The A3 Adenosine Receptor is Highly Expressed in Tumor vs. Normal Cells: Potential Target for Tumor Growth Inhibition", <u>Clinical Cancer Research</u> , Vol. 10, pages 4472-4479, 2004.	
	AS	S. GESSI et al., "Elevated expression of A ₃ adenosine receptors in human colorectal cancer is reflected in peripheral blood cells", <u>Clinical Cancer Research</u> , Vol. 10, pages 5895-5901, 2004.	

Examiner Signature	/Satyendra Singh/	Date Considered	09/27/2008
--------------------	-------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SS/

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.